Forte Biosciences (FBRX) Debt to Equity (2016 - 2019)
Historic Debt to Equity for Forte Biosciences (FBRX) over the last 4 years, with Q2 2019 value amounting to $0.61.
- Forte Biosciences' Debt to Equity rose 762.99% to $0.61 in Q2 2019 from the same period last year, while for Jun 2019 it was $0.61, marking a year-over-year increase of 762.99%. This contributed to the annual value of $0.45 for FY2018, which is 78360.29% up from last year.
- According to the latest figures from Q2 2019, Forte Biosciences' Debt to Equity is $0.61, which was up 762.99% from $0.54 recorded in Q1 2019.
- In the past 5 years, Forte Biosciences' Debt to Equity registered a high of $0.61 during Q2 2019, and its lowest value of -$0.08 during Q4 2016.
- Over the past 4 years, Forte Biosciences' median Debt to Equity value was $0.08 (recorded in 2017), while the average stood at $0.25.
- The largest annual percentage gain for Forte Biosciences' Debt to Equity in the last 5 years was 152864.13% (2019), contrasted with its biggest fall of 762.99% (2019).
- Forte Biosciences' Debt to Equity (Quarter) stood at -$0.08 in 2016, then surged by 161.96% to $0.05 in 2017, then skyrocketed by 783.6% to $0.45 in 2018, then soared by 34.29% to $0.61 in 2019.
- Its Debt to Equity was $0.61 in Q2 2019, compared to $0.54 in Q1 2019 and $0.45 in Q4 2018.